News & Updates
Filter by Specialty:
Long-term TAF works against resistant HBV, poses no excess cardiovascular risk
Tenofovir alafenamide (TAF) shows sustained safety and efficacy in heavily pretreated patients with multidrug-resistant hepatitis B virus (HBV) through 3 years of treatment, albeit leading to elevations in cholesterol levels.
Long-term TAF works against resistant HBV, poses no excess cardiovascular risk
17 Nov 2021
Statins reduce hepatocellular carcinoma risk in cirrhotic patients
The risk of hepatocellular carcinoma (HCC) among patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis is low, reveals a recent study. In addition, dose-dependent statin can substantially lower the risk of HCC in patients with NASH cirrhosis.
Statins reduce hepatocellular carcinoma risk in cirrhotic patients
17 Nov 2021
Finerenone confers consistent cardiorenal benefits in patients with CKD and T2D regardless of SGLT-2i use
In patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) who were receiving the novel nonsteroidal MRA* finerenone, use of SGLT-2is** at baseline did not influence treatment outcomes, according to a subgroup analysis of the FIDELITY*** trial presented at ASN 2021.
Finerenone confers consistent cardiorenal benefits in patients with CKD and T2D regardless of SGLT-2i use
17 Nov 2021
TAF rivals TDF for CHB suppression after orthotopic liver transplantation
Switching from tenofovir disoproxil fumarate (TDF) regimens to tenofovir alafenamide (TAF) monotherapy demonstrates long-term efficacy and safety in orthotopic liver transplantation (OLT) recipients with chronic hepatitis B virus (HBV) infection, reports a study presented at The Liver Meeting Digital Experience 2021, by the American Association for the Study of Liver Diseases (AASLD 2021).
TAF rivals TDF for CHB suppression after orthotopic liver transplantation
17 Nov 2021
Tenofovir alafenamide safe to use in breastfeeding mothers with CHB
The first human pharmacokinetic study of tenofovir alafenamide (TAF; commercially sold as Vemlidy) monotherapy in breastfeeding women with chronic hepatitis B (CHB) has found low concentrations of TAF and tenofovir in the breastmilk, with negligible exposure to infants.